| 2009 |
Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, Gregorio LHd, Hadji P, Hofbauer LC, Álvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. January 2009;24(1):153-161. |
25 |
19 |
| 2010 |
Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW; Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. October 2010;25(10):2256-2265. |
19 |
12 |
| 2015 |
Ominsky MS, Libanati C, Niu Q-T, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW. Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous bmd gains with denosumab. J Bone Miner Res. July 2015;30(7):1280-1289. |
12 |
7 |
| 2019 |
Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwiński E, de Gregόrio LH, Malouf-Sierra J, Reginster J-Y, Wang A, Wagman RB, Lewiecki EM. Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res. June 2019;34(6):1033-1040. |
12 |
9 |
| 2020 |
Dempster DW, Chines A, Bostrom MP, Nieves JW, Zhou H, Chen L, Pannacciulli N, Wagman RB, Cosman F. Modeling‐based bone formation in the human femoral neck in subjects treated with denosumab. J Bone Miner Res. July 2020;35(7):1282-1288. |
2 |
1 |
| 2017 |
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. July 2017;5(7):513-523. |
47 |
35 |
| 2015 |
Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int. December 2015;26(12):2773-2783. |
22 |
15 |
| 2017 |
McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. May 2017;28(5):1723-1732. |
18 |
18 |